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Abstract: Ciprofloxacin, a member of the fluoroquinolone class, is an antibiotic used as a treatment 
for infections including the Anthrax bacteria. Studies concerning the safety and efficacy of 
ciprofloxacin have been controversial with respect to nephrotoxicity. Using rats orally treated with 
ciprofloxacin (400mg/kg/d), the effects of this drug were analyzed measuring several indications of 
nephrotoxicity: -NAG, creatinine, blood urea nitrogen, and sodium and potassium levels in blood 
samples. Additionally, histological analyses were performed. -NAG values, a measure of early renal 
damage, were significantly increased after 4 and 7 days of treatment (p = 0.001 and p = 0.004, 
respectively) compared with control rats. However, 7 days post-treatment, -NAG values decreased to 
control levels indicative that adaptive responses were induced to prevent nephrotoxicity. These results 
indicate that ciprofloxacin in doses comparable to those commonly prescribed does not induce 
nephrotoxicity. Altogether, they further support the idea that ciprofloxacin can be safely used. 
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INTRODUCTION 
 
 Although antibiotics have revolutionized the 
management of many illnesses, they often have 
several side effects, one of the most important being 
the increased incidence of acute and chronic renal 
reactions[1]. The kidney is a preferential target for 
several environmental toxins and therapeutic agents[2-
6]
 such as antibiotics, which interact with the kidney, 
especially affecting its central role in excretion, 
namely glomerular filtration and creatinine 
clearance[7,8]. Such effects could lead to acute and/or 
chronic renal insufficiency after long term usage[9,10]. 
Wide ranges of toxicity have been reported, with 
commonly acknowledged rates of 5% to 14% for 
nephrotoxicity[11]. The risk for nephrotoxicity is 
further increased by concurrent administration of 
other potential nephrotoxins, including amphotericin 
B, cyclosporine, diuretics, or cisplatin[12]. 
 Ciprofloxacin, one of the newer generation of 
antibacterial agents, while effective in treating both 
gram (-) and gram (+) bacterial infections[13] has, like 
other antibiotics, nephrotoxic actions[14]. The 
excretion of ciprofloxacin by the kidneys is believed 
to be the cause of renal damage[15-17], however, the 
mechanisms of ciprofloxacin nephrotoxicity is not 
clear. For  this    reason, we decided to study this 
issue    using   a rodent    model   orally   treated  with  
ciprofloxacin. We evaluated N-acetyl--D-
glucosaminidase (-NAG), an early marker of renal 
damage[18,19], and several nephrotoxicity indicators: 
creatinine clearance, blood urea nitrogen (BUN), and 
sodium and potassium levels. 
 
MATERIALS AND METHODS 
 
Reagents: Ciprofloxacin hydrochloride was obtained 
from Bayer, Germany. All the other chemicals were of the 
highest grade of purity commercially available. 
 
Animals and Experimental Design: Female Sprague-
Dawley rats (n = 24, 180-250g), obtained from Akdeniz 
University Animal Laboratories (Antalya, Turkey), were 
maintained individually in metabolic cages and fed ad 
libitum. 
 Rats were divided into four groups of 6 rats each: 
Group one - control rats; Group two - rats treated with 
ciprofloxacin for 4 days; Group three - rats treated with 
ciprofloxacin for 7 days; and Group four - rats treated 
with ciprofloxacin for 7 days and then stopped for 7 days. 
Ciproflaxin was given as a single dose 1 day 
(400mg/kg/d) by nasogastric sonda.  
 
Biochemical Determinations: Urine and blood samples 
were collected on 0, 4, 7 and 14 days, respectively. A 
certain   amount  of  the urine  samples were kept at +4°C,  
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the remaining urine samples and blood were kept at -
20°C. After collection of samples, all rats were 
sacrificed, and kidneys were removed and stored in 
buffered formaldehyde up to two weeks. The volume 
and pH of urine samples; creatinine, BUN, sodium 
and potassium levels in blood samples; and -NAG 
and creatinine levels in urine samples were 
determined.  
 
Determination of -NAG Levels: -NAG values were 
determined colorimetrically by the hydrolysis of 
sodium salt of its substrate 3-3' dichloro phenol 
sulfophthalein-N-acetyl-ß-D-glucosaminide. A 
standard curve of 0 to 7 U/L -NAG was constructed. 
1 ml substrate solution was pipetted into test tubes. 
After incubation for 5 minutes at 37°C, 0.05 ml of 
sample was pipetted into test tubes. Blanks, standards 
and samples were incubated for 15 minutes at 37°C, 
stop solution added, and colorimetric values 
determined. 
 
Determination of BUN, Sodium, Potassium and 
Creatinine Levels: BUN, sodium, potassium and 
creatinine levels were measured in a Hitachi 911 
analyzer.  
 
Immunocytochemistry: At the end of the experiments, 
all rats were sacrificed, kidneys were removed, and 
stored in buffered formaldehyde up to two weeks, 
followed by paraffin embedding.  After sectioning, 
the rat kidney morphology was analyzed for each 
animal, blinded to the observer, following staining 
with hematoxylin-eosin and visualized by light 
microscopy. 
 
Statistics: Statistical significance was determined 
using the ANOVA test when parametric standards 
were present or by the Kruskall-Wallis test when 
parametric standards were not present. In the 
conditions that F value was not meaningful, Sheffe 
was used as the post-hoc test. For comparison of the 
biochemical parameters of the groups, Mann-
Whitney U test was used. Significance was accepted 
as p < 0.05. Results are presented as mean ± SEM of 
the indicated number of experiments. 
 
RESULTS 
 
 The excretion levels of -NAG, as well as the 
levels of sodium, potassium, and BUN are shown in 
Table 1. No significant differences were observed for 
BUN (p = 0.4), sodium (p = 0.5), and potassium (p = 
0.4) levels as well as pH (p = 0.4) values between 
control animals and animals treated for 4 days nor 
between the subjects treated for 7 and 14 days. 
Furthermore, no significant difference was observed for 
the creatinine clearance in all groups of animals. The 
weights of the rats remained unchanged. 
 -NAG values increased significantly in group 2 (4 
day treatment) (p = 0.001) and remained significantly 
higher after 7 days (p=0.004) when compared with 
control rats. The -NAG values of the 4 and 7 days 
treated rats were not significantly different (p = 0.06), The 
values are significantly at lower levels in the 14 day 
treated group when compared with the 7 days treated 
group (p = 0.02) (Figure 1) returning to the same levels as 
control group (p=0.8). No pathologic symptoms were 
observed in kidney sections from any of the experimental 
animals stained with hematoxylin-eosin (not shown). 
 
DISCUSSION 
 
 Ciprofloxacin is an antibiotic used to treat bacterial 
infections in many different parts of the body. This 
antibiotic is approved for the inhaled form of Anthrax 
after an individual has been exposed to the agent. 
However, until now, the safety and effectiveness of this 
compound remained unclear. We investigated the effect 
of orally administrated ciprofloxacin in rat kidneys in a 
dosage 400 mg/kg/day, in accordance with previous 
studies[20,21]. Our results for sodium, potassium, and BUN 
levels (Table 1) are in accordance with previous studies 
[22,23]
. 
 
Table 1. Relationship between duration of therapy and 
concentrations of various parameters 
 Parameter (SE) conc 
 Na 
mEq/L 
K 
mEq/L 
BUN 
mg/dL 
Creatinine 
clearance 
mg/min 
B-NAG 
U/L 
1 134 ± 4.6 4.5 + 0.3 19.3 + 0.9 0.37 + 0.02 7.8 + 1.3 
2 138 + 2.8 4.2 + 0.3 15.6 + 0.1 0.34 + 0.03 27.1 + 5.7 
3 138 + 0.9 4.6 + 0.2 15.5 + 0.9 0.40 + 0.06 15.6 + 2.1 
4 135 + 1.2 4.2 + 0.3 16.1 + 0.6 0.10 + 0.02 7.5 + 1.2 
 
 Although the creatinine clearance showed slight 
variation in rats treated with ciprofloxacin, these 
differences were not significant when compared with 
control animals (p > 0.05). Basaran et al.[23] observed an 
increase in creatinine clearance during ciprofloxacin 
treatment. The different results obtained are most likely 
due to differences in the methodology used. However, 
similarly to our results, they did not find histological 
changes in the kidney. Furthermore, Falkenberg and 
Mondorf[24] found no tubular damage in their 
ciprofloxacin nephrotoxicity study.  
 To determine renal deterioration at early stages, -
NAG values were analyzed and it was observed that 
ciprofloxacin therapy alters -NAG concentrations (Table 
1; Figure 1), which indicates that -NAG is a suitable 
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parameter for the evaluation of renal function 
damage. Importantly, it was observed that -NAG 
values return to normal after the treatment is stopped 
(Table 1). Yazaki et al.[25] observed that isepamicin, a 
broad spectrum aminoglycoside, increased NAG, 
BUN and serum creatinine. However, these effects 
could be prevented by fleroxacin, a broad-range 
antimicrobial spectrum.  
 
 
 
Fig. 1: ß-NAG values of the 4 day treatment group. 
 
 -NAG values were highest in the 4 day treated 
animals and were lower in the 7 day treated  rats.  
Similarly, William and Kenneth[17] reported 
improvement in the clinical symptoms of  
nephrotoxicity in patients after ciprofloxacin 
treatment was stopped. The fact that the levels of -
NAG in group four is similar to that of control 
animals suggests that the animals develop adaptive 
responses that lead to the normalization of -NAG 
values.  
 Overall, we did not observe any dose-dependent 
toxicity induced by ciprofloxacin, although previous 
studies reported a dose-dependent toxicity[26]. 
Altogether, our data suggests that ciprofloxacin does 
not have any long-term effect on kidney function or 
morphology, despite the higher levels of -NAG 
observed during the treatment. The dosage of used in 
this study falls in the range given to human subjects 
(for more information, see 
http://www.nlm.nih.gov/medlineplus/druginfo/uspdi/
202656.html).  In conclusion, despite the increased 
levels of -NAG in early stages of drug 
administration, ciprofloxacin does not exert 
nephrotoxicity.  
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